Epirubicin, Cisplatin, Capecitabine, Panitumumab + Epirubicin, Cisplatin, Capecitabine
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Stomach Neoplasms
Conditions
Stomach Neoplasms, Gastroesophageal Junction Neoplasms
Trial Timeline
Oct 1, 2010 → Aug 1, 2017
NCT ID
NCT01234324About Epirubicin, Cisplatin, Capecitabine, Panitumumab + Epirubicin, Cisplatin, Capecitabine
Epirubicin, Cisplatin, Capecitabine, Panitumumab + Epirubicin, Cisplatin, Capecitabine is a phase 2 stage product being developed by Amgen for Stomach Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT01234324. Target conditions include Stomach Neoplasms, Gastroesophageal Junction Neoplasms.
What happened to similar drugs?
1 of 8 similar drugs in Stomach Neoplasms were approved
Approved (1) Terminated (1) Active (6)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01234324 | Phase 2 | Completed |
Competing Products
20 competing products in Stomach Neoplasms